Continue to Site

LeMaitre Vascular beats The Street in Q4, grows sales 5%

February 25, 2022 By Danielle Kirsh

LeMaitre Vascular (NSDQ:LMAT) posted fourth-quarter results that beat the overall consensus forecast on Wall Street.

The Burlington, Massachusetts-based company yesterday evening reported profits of $6.2 million, or 28¢ per share, on sales of $39.5 million for the three months ended Dec. 31, 2021, for a bottom-line loss of -12.2% on sales growth of 5.21% compared with Q4 2020.

Earnings per share were 28¢, 3¢ ahead of The Street, where analysts were looking for sales of $39.7 million.

LeMaitre Vascular expects Q1 2022 sales to be in the range of $37.7 million and $39.7 million with an EPS range of 26¢ to 30¢. Full-year revenue is expected to be in the range of $162 million to $166 million with an EPS range estimate of $1.35 to $1.45.

Shares in LMAT were down slightly at $45.65 apiece in morning trading today.

MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1%.

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Tubing + Extrusion, Medical Design & Outsourcing and MassDevice. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.